Stifel analyst Stephen Willey lowered the firm’s price target on Abeona Therapeutics (ABEO) to $20 from $21 and keeps a Buy rating on the shares. The firm views the recent activation of the first Zevaskyn Qualified Treatment Center and the anticipated treatment of the first patient in August 2025 as “an encouraging development,” the analyst tells investors in a Q1 recap note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics price target raised to $27.50 from $25 at Alliance Global Partners
- Abeona Therapeutics reports Q1 EPS (24c), consensus (35c)
- Abeona Therapeutics sees cash runway through early 2026
- Abeona, Lurie Children’s opens first center for ZEVASKYN gene therapy
- Abeona Therapeutics: Strong Buy Rating Backed by Financial Stability and Strategic Growth Initiatives